Literature DB >> 26391884

Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.

Brett Doble1, Paula Lorgelly2.   

Abstract

PURPOSE: To determine the external validity of existing mapping algorithms for predicting EQ-5D-3L utility values from EORTC QLQ-C30 responses and to establish their generalizability in different types of cancer.
METHODS: A main analysis (pooled) sample of 3560 observations (1727 patients) and two disease severity patient samples (496 and 93 patients) with repeated observations over time from Cancer 2015 were used to validate the existing algorithms. Errors were calculated between observed and predicted EQ-5D-3L utility values using a single pooled sample and ten pooled tumour type-specific samples. Predictive accuracy was assessed using mean absolute error (MAE) and standardized root-mean-squared error (RMSE). The association between observed and predicted EQ-5D utility values and other covariates across the distribution was tested using quantile regression. Quality-adjusted life years (QALYs) were calculated using observed and predicted values to test responsiveness.
RESULTS: Ten 'preferred' mapping algorithms were identified. Two algorithms estimated via response mapping and ordinary least-squares regression using dummy variables performed well on number of validation criteria, including accurate prediction of the best and worst QLQ-C30 health states, predicted values within the EQ-5D tariff range, relatively small MAEs and RMSEs, and minimal differences between estimated QALYs. Comparison of predictive accuracy across ten tumour type-specific samples highlighted that algorithms are relatively insensitive to grouping by tumour type and affected more by differences in disease severity.
CONCLUSIONS: Two of the 'preferred' mapping algorithms suggest more accurate predictions, but limitations exist. We recommend extensive scenario analyses if mapped utilities are used in cost-utility analyses.

Entities:  

Keywords:  Cancer; Condition-specific non-preference-based measures; External validation; Generic preference-based measures; Mapping; Quality of life

Mesh:

Year:  2015        PMID: 26391884     DOI: 10.1007/s11136-015-1116-2

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  51 in total

1.  Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D.

Authors:  Matthijs M Versteegh; Annemieke Leunis; Jolanda J Luime; Mike Boggild; Carin A Uyl-de Groot; Elly A Stolk
Journal:  Med Decis Making       Date:  2011-11-22       Impact factor: 2.583

Review 2.  EuroQol: the current state of play.

Authors:  R Brooks
Journal:  Health Policy       Date:  1996-07       Impact factor: 2.980

3.  US valuation of the EQ-5D health states: development and testing of the D1 valuation model.

Authors:  James W Shaw; Jeffrey A Johnson; Stephen Joel Coons
Journal:  Med Care       Date:  2005-03       Impact factor: 2.983

4.  Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences.

Authors:  Ralph Crott; Andrew Briggs
Journal:  Eur J Health Econ       Date:  2010-05-16

5.  Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients.

Authors:  Eun-ju Kim; Su-Kyoung Ko; Hye-Young Kang
Journal:  Qual Life Res       Date:  2011-10-20       Impact factor: 4.147

6.  Mapping to obtain EQ-5D utility values for use in NICE health technology assessments.

Authors:  Louise Longworth; Donna Rowen
Journal:  Value Health       Date:  2013 Jan-Feb       Impact factor: 5.725

7.  Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group.

Authors:  D Osoba; N Aaronson; B Zee; M Sprangers; A te Velde
Journal:  Qual Life Res       Date:  1997-03       Impact factor: 4.147

8.  Mapping from disease-specific to generic health-related quality-of-life scales: a common factor model.

Authors:  Guobing Lu; J E Brazier; A E Ades
Journal:  Value Health       Date:  2012-09-25       Impact factor: 5.725

Review 9.  Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database.

Authors:  Helen Dakin
Journal:  Health Qual Life Outcomes       Date:  2013-09-05       Impact factor: 3.186

10.  Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study.

Authors:  Karin Jordan; Irina Proskorovsky; Philip Lewis; Jack Ishak; Krista Payne; Noreen Lordan; Charalampia Kyriakou; Cathy D Williams; Sarah Peters; Faith E Davies
Journal:  Support Care Cancer       Date:  2014-02       Impact factor: 3.603

View more
  14 in total

1.  Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients.

Authors:  Hosein Ameri; Mahmood Yousefi; Mehdi Yaseri; Azin Nahvijou; Mohammad Arab; Ali Akbari Sari
Journal:  J Gastrointest Cancer       Date:  2020-03

2.  Mapping the Chinese Version of the EORTC QLQ-BR53 Onto the EQ-5D-5L and SF-6D Utility Scores.

Authors:  Tong Liu; Shunping Li; Min Wang; Qiang Sun; Gang Chen
Journal:  Patient       Date:  2020-10       Impact factor: 3.883

3.  Patient-reported health state utilities in metastatic gastroenteropancreatic neuroendocrine tumours - an analysis based on the CLARINET study.

Authors:  Yang Meng; Grant McCarthy; Anthony Berthon; Jerome Dinet
Journal:  Health Qual Life Outcomes       Date:  2017-06-29       Impact factor: 3.186

4.  Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L.

Authors:  Paula K Lorgelly; Brett Doble; Donna Rowen; John Brazier
Journal:  Qual Life Res       Date:  2016-11-09       Impact factor: 4.147

5.  Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study.

Authors:  Yasuhiro Hagiwara; Takeru Shiroiwa; Kojiro Shimozuma; Takuya Kawahara; Yukari Uemura; Takanori Watanabe; Naruto Taira; Takashi Fukuda; Yasuo Ohashi; Hirofumi Mukai
Journal:  Pharmacoeconomics       Date:  2018-02       Impact factor: 4.981

Review 6.  Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals.

Authors:  Micah Rose; Stephen Rice; Dawn Craig
Journal:  Pharmacoecon Open       Date:  2018-06

7.  The validation of published utility mapping algorithms: an example of EORTC QLQ-C30 and EQ-5D in non-small cell lung cancer.

Authors:  Joanne Gregory; Matthew Dyer; Christopher Hoyle; Helen Mann; Anthony J Hatswell
Journal:  Health Econ Rev       Date:  2020-04-21

8.  Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments.

Authors:  Fan Yang; Nancy Devlin; Nan Luo
Journal:  Eur J Health Econ       Date:  2018-06-14

9.  Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.

Authors:  Iftekhar Khan; Steve Morris; Nora Pashayan; Bashir Matata; Zahid Bashir; Joe Maguirre
Journal:  Health Qual Life Outcomes       Date:  2016-04-12       Impact factor: 3.186

10.  Measuring quality of life in opioid-induced constipation: mapping EQ-5D-3 L and PAC-QOL.

Authors:  Anthony James Hatswell; Stefan Vegter
Journal:  Health Econ Rev       Date:  2016-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.